Structure Therapeutics, Inc. · NASDAQ:GPCR
Structure Therapeutics — Corporate Update (March 2026)
35 slides from Structure Therapeutics's corporate update, Mar 16, 2026
Slide 1: Aleniglipron Topline ACCESS II and Supplementary Studies
1 March 16, 2026 Aleniglipron Topline ACCESS II and Supplementary Studies
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward - looking statements, including
Slide 3: Today's Update
3 Closing Raymond Stevens Interim Data from ACCESS OLE and Body Composition Studies Blai Coll Topline 44 - week Data from ACCESS II Study Blai Coll, M.D., Ph.D, Chief Medical Officer Today’s Update Introduction Raymond Stevens, Ph.D, Chief Executive Officer 1 2 3 4 Q&A Blai Coll, Raymond Stevens Jun
Slide 4: Aleniglipron Obesity Data Summary
4 March 2026 ACCESS OLE continuing at 120 mg: 56 week body weight loss: o Up to 16.2%; n o evidence of plateauing o 2% AE - related treatment discontinuations ACCESS II: 44 week p lacebo - adjusted mean weight loss: o 16.3% at 180 mg and 16.0% at 240 mg; no evidence of plateauing For those participa
Slide 5: Aleniglipron Patient Journey to Chronic Weight Management
5 Aleniglipron Patient Journey to Chronic Weight Management Key Questions 44 weeks 120 mg 180 mg 240 mg ACCESS OLE Interim – Week 36 to 56 2.5 mg start 3 0 mg 45/90/120mg 120 mg Body Composition Interim through Week 20 2.5 mg start to 30 mg March 2026 1. What is the top dose? 2. Does weight loss con
Slide 6: Aleniglipron Patient Journey to Chronic Weight Management
6 Aleniglipron Patient Journey to Chronic Weight Management 44 weeks 120 mg 180 mg 240 mg 1. What is the top dose? 2. Does weight loss continue beyond 36 weeks?
Slide 7: ACCESS II Study Design and Endpoints
7 ACCESS II Focused on 180 mg and 240 mg Doses at 44 Weeks 240 mg 180 mg Weeks 0 20 24 28 32 36 Baseline 180 mg 120 mg 90 mg 60 mg 30 mg 15 mg 5 mg Study Details N= 73 Participants with: • Body mass index (BMI) ≥ 30 kg/m 2 or • BMI ≥ 27 kg/m 2 with ≥ 1 weight - related comorbidity Number of sites: 1
Slide 8: Baseline Demographics and Characteristics
8 Placebo N=12 Aleniglipron Overall N=61 Characteristics Mean (SD) or N (%) 51.8 (12.9) 49.8 (14.5) Age, years 8 (66.7) 38 (62.3) Sex, female 104.3 (12.38) 116.2 (31.9) Weight, kg 36.8 (5.1) 39.9 (8.4) Body mass index, kg/m 2 5.4 (0.36) 5.6 (0.35) HbA1c, % 122.6 (11.4) 122.2 (12.2) Systolic Blood Pr
Slide 9: Aleniglipron Achieved Greater Weight Loss at 44 Weeks
9 Aleniglipron Achieved Greater Weight Loss at 44 weeks Least - Squares Mean (LSM) Change (%) Body Weight *LS Mean Difference based on Primary Efficacy Estimand and MMRM model 37 lbs 39 lbs 33 lbs - 14.7% ( - 20.3 to - 9.1) P<0.0001 - 16.3% ( - 21.7 to - 10.9) P<0.0001 - 16.0% ( - 21.5 to - 10.6) P<
Slide 10: Aleniglipron Achieved Secondary Efficacy Endpoints
10 Aleniglipron Achieved Secondary Efficacy Endpoints • 180 mg dose cohort: o 9 3% achieved ≥ 10% body weight reduction o 61% achieved ≥ 15% body weight reduction o 32% of participants achieved ≥ 20% body weight reduction based on additional exploratory analysis
Slide 11: Tolerability in Re-Randomized Participants over Weeks 8-44
11 Tolerability in Re - Randomized Participants over Weeks 28 - 44 * Post Re - Randomization • Higher vomiting in the 240 mg cohort compared to 120 mg and 180 mg • 3.7% (1/27) AE - related treatment discontinuation across all doses ** *O ne participant in the 180 mg dose discontinued due to an AE on
Slide 12: Tolerability Profile in the ACCESS II post re-randomization
12 Tolerability Profile in the ACCESS II – post re - randomization Post Re - Randomization (Weeks 28 – 44)* Placebo N=10 Aleniglipron 240 mg N=9 Aleniglipron 180 mg N=10 Aleniglipron 120 mg N=8 N (%) Reporting at least one event 3 (30) 5 (55.6) 5 (50) 2 (25) Any TEAE 0 0 0 0 Any SAE 0 0 1 (10) 0 Any
Slide 13: Summary of Topline Data from ACCESS II
13 Summary of Topline Data from ACCESS II • Efficacy o Potential best - in - class efficacy for an oral GLP - 1RA with 180 mg dose achieving 16.3% weight loss (placebo - adjusted) at 44 weeks • Tolerability o Low number (3.7%) of AEs leading to discontinuations across all doses in re - randomized pa
Slide 14: Aleniglipron Patient Journey to Chronic Weight Management
14 Aleniglipron Patient Journey to Chronic Weight Management ACCESS OLE Interim – Week 36 to 56 2.5 mg start 3 0 mg 45/90/120mg 120 mg 2. Does weight loss continue beyond 36 weeks? 4. Does tolerability improve starting at 2.5 mg?
Slide 15: ACCESS OLE Beyond 36 Weeks and 2.5 mg Starting Dose
15 120 mg ACCESS OLE Beyond 36 weeks and 2.5 mg Starting Dose Baseline Titration Phase (every 4 weeks) Maintenance Phase (at target dose) ACCESS Primary Endpoint 30 15 5 N=45 N=65 N=64 N=56 *OLE is ongoing up to 72 weeks 45 mg 90 mg 60 30 15 5 120 mg 60 30 15 5 90 Pooled Placebo 75 120 mg 90 60 30 2
Slide 16: Aleniglipron Continued to Demonstrate Weight Loss Beyond 36 Weeks
16 Aleniglipron Continued to Demonstrate Weight Loss Beyond 36 weeks *Study ongoing and interim data as of February 20 th , 2026. No statistical model applied Descriptive Body Weight Reduction ACCESS OLE Period Interim: Week 36 – 56 ACCESS Double Blind (DB) Treatment Period Baseline to Week 36 Mean
Slide 17: Improved Tolerability with the 2.5 mg Starting Dose
17 Improved Tolerability with the 2.5 mg Starting Dose • Occasional events of nausea reported and no events of vomiting • No study drug discontinuations in participants starting the OLE at 2.5 mg of aleniglipron after a median follow up of 20 weeks Study ongoing Study ongoing Nausea - Aleniglipron (
Slide 18: Tolerability Profile in ACCESS OLE
18 Tolerability Profile in ACCESS OLE: Weeks 36 to 56 Study Ongoing Aleniglipron in the OLE (median follow up of 20 weeks after finalization of the double - blind treatment period) N (%) Reporting at least one event Placebo - cross over * 120 mg 90 mg 45 mg Arm in the double - blind treatment period
Slide 19: Summary of Interim Data of ACCESS OLE
19 Summary of Interim Data of ACCESS OLE • Efficacy o Clinically relevant and additional body weight loss beyond 36 weeks, achieving up to 16.2% weight loss at 120 mg • Tolerability o Very low (2.0%) AE - related treatment discontinuations o Tolerability improved with 2.5 mg starting dose with no vo
Slide 20: Aleniglipron Patient Journey to Chronic Weight Management
20 Aleniglipron Patient Journey to Chronic Weight Management Body Composition Interim through Week 20 2.5 mg start to 30 mg 3 . Is there weight loss at low doses? 4 . Does tolerability improve starting at 2.5 mg?
Slide 21: Body Composition Study Design
21 Body Composition Study to Further Evaluate Improved Tolerability with 2.5 mg Starting Dose Body Composition Study Objectives • Assess body fat loss over 40 weeks to inform body composition endpoints in Phase 3 • Evaluate tolerability with 2.5 mg starting dose Study Details N=71 Participants with:
Slide 22: Baseline Demographics and Characteristics (Body Composition Study)
22 Baseline Demographics and Characteristics (Body Composition Study) Placebo N=12 Aleniglipron N=59 Characteristics Mean (SD) or N (%) 48.8 (16.4) 54.5 (11.4) Age, years, mean 8 (66.7) 38 (64.4) Sex, female 111.2 (20.8) 108.0 (20.2) Weight, kg 39.6 (6.8) 38.1 (6.2) Body mass index, kg/m 2 5.6 (0.4)
Slide 23: Aleniglipron Continued to Demonstrate Weight Loss with 2.5 mg Starting Dose
23 Aleniglipron Continued to Demonstrate Weight Loss Body with 2.5 mg Starting Dose Percent Change in Body Weight, % * Study ongoing and pre - specified interim data as of February 20 th , 2026. No statistical model applied • Clinically significant body weight reduction up to 30 mg in participants s
Slide 24: Low Prevalence of Nausea and Vomiting Over Time
24 Low Prevalence of Nausea and Vomiting Over Time Study ongoing Study ongoing Study ongoing Study ongoing • Events of nausea reported at the titration steps (<10%) • No events of vomiting while at the 2.5 mg starting dose • Very low occurrence of vomiting over time • 2 (3.4%) AE - related treatment
Slide 25: Tolerability Profile in the Body Composition Study
25 Tolerability Profile in the Body Composition Study * Study Ongoing Placebo N=12 Aleniglipron N=59 N (%) Reporting at least one event NA 2.5 mg Starting Dose 10 (83.3) 50 (84.7) Any TEAE 0 2 (3.4) Any TEAE leading to discontinuation of treatment 3 (33.3) 30 (50.8) Nausea 1 (8.3) 14 (23.7) Vomiting
Slide 26: Summary of Interim Data of Body Composition
26 Summary of Interim Data of Body Composition • Efficacy o Initial signs of body weight reduction up to 6.8% at 20 - week median follow up • Tolerability o Clinically manageable tolerability profile and very low (3.4%) study drug discontinuations due to AEs Body Composition Interim through Week 20
Slide 27: Tolerability Improvement with Start Low and Go Slow Titration
27 55.3% 24.4% 8.3% 45.4% 14.4% 2.1% 0% 10% 20% 30% 40% 50% 60% % of participants Tolerability Improvement Observed with Start Low (2.5 mg) and Go Slow Titration Strategy *Studies ongoing and interim data from a pre - specified analysis. Interim data as of February 20 th , 2026 Nausea Vomiting Disco
Slide 28: Aleniglipron Patient Journey to Chronic Weight Management
28 Aleniglipron Patient Journey to Chronic Weight Management Body Composition Interim through Week 20 2.5 mg start to 30 mg 5. Does aleniglipron maintain absence of off - target safety? 44 weeks 120 mg 180 mg 240 mg ACCESS OLE Interim – Week 36 to 56 2.5 mg start 3 0 mg 45/90/120mg 120 mg
Slide 29: Aleniglipron Continues to Demonstrate Favorable Off-Target Safety Results
29 Aleniglipron Continues to Demonstrate Favorable Off - Target Safety Results • No cases of drug - induced liver injury (DILI) • No cases of ALT or AST ≥ 10x upper limit of normal (ULN) • All cases of elevated ALT and AST resolved without treatment modification or discontinuation * Interim data as
Slide 30: Aleniglipron Patient Journey: Key Questions Answered
30 Aleniglipron Patient Journey to Chronic Weight Management Key Questions 1. What is the top dose? Potential best - in - class efficacy – 16.3% weight loss at 180 mg dose March 2026 2. Does weight loss continue beyond 36 weeks? ACCESS II and ACCESS OLE No evidence of plateauing at 44 weeks (ACCESS
Slide 31: Closing
31 Closing Raymond Stevens
Slide 32: 2026: A Transformational Year as Aleniglipron Advances into Phase 3
32 Phase 3 Phase 2 Phase 1 IND - enabling/ DC Lead Opt Discovery Study / Focus Molecule(s) Program Phase 3 Registrational Aleniglipron (GSBR - 1290) Selective GLP - 1 Receptor Agonist Backbone ACCESS (+ OLE) ACCESS II (+ Extension) Diabetes/Obesity SWITCH Study Body Composition ACCG - 2671 (DACRA) A
Slide 33: Access to Obesity Treatments Remains a Worldwide Unmet Need
33 1. August 2025 Symphony Health prescriptio n data and 2025 Evaluate Pharma sales data ; Morgan Stanley Mounjaro+Zepbound Script tracker . March 2026 2. Trust for America’s Health Rep ort https://www.tfah .org/report - details/stateofobesity2019/#:~:text=Obesity%20is%20a%20growing%20epidemic,100%2
Slide 34: Q&A
THERAPEUTICS Q&A
Slide 35: Our Mission: Making medicines more accessible to all
35 Our Mission Making medicines more accessible to all
Structure Therapeutics — Corporate Update (March 2026) on 6ix